Bone marrow response as a potential biomarker of outcomes in glioblastoma patients

Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

(2014) Jayson I. L. Bastien et al.   CANCER

Pros and cons of current brain tumor imaging

(2014) B. M. Ellingson et al.   NEURO-ONCOLOGY

Emerging Therapies for Glioblastoma

(2014) Alissa A. Thomas et al.   JAMA Neurology

Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival

(2012) Matt Williams et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

(2012) Shota Tanaka et al.   Nature Reviews Clinical Oncology

Molecular diagnostics of gliomas: the clinical perspective

(2010) Ghazaleh Tabatabai et al.   ACTA NEUROPATHOLOGICA

The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations

(2010) Andreas Von Deimling et al.   BRAIN PATHOLOGY

Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value

(2010) A. X. Zhu et al.   CLINICAL CANCER RESEARCH

Temozolomide in malignant gliomas: current use and future targets

(2009) J. Lee Villano et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Anti-Apoptosis Mechanisms in Malignant Gliomas

(2008) David S. Ziegler et al.   JOURNAL OF CLINICAL ONCOLOGY